

# Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 60th ASH Annual Meeting

November 1, 2018

## - Company to Present One Oral Presentation and Two Posters -

LONDON, Nov. 1, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will present one oral and two poster presentations related to its AUTO3 and AUTO5 programs at the 60<sup>th</sup>American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 1-4, 2018 in San Diego, CA.

### The oral presentation details are as follows:

Publication Number: 279 Submission ID: 118616 Session Name: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next? TITLE: Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-cell Therapy, in Pediatric Patients with Relapse/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL): AMELIA Study Session Date: Sunday, December 2, 2018 Session Time: 7:30 AM - 9:00 AM Presentation Time: 8:00 AM Room: San Diego Convention Center, Ballroom 20D

## The poster presentation details are as follows:

Publication Number: 1679 Submission ID: 119197 Session Name: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I TITLE: Study of AUTO3, the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22, Followed by Anti-PD1 Consolidation in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): ALEXANDER Study Date: Saturday, December 1, 2018 Presentation Time: 6:15 PM - 8:15 PM Location: San Diego Convention Center, Hall GH

Publication Number: 1661 Submission ID: 119564 Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I TITLE: Structure guided engineering of highly specific Chimeric Antigen Receptors for the complete treatment of T cell lymphomas Date: Saturday, December 1, 2018 Presentation Time: 6:15 PM - 8:15 PM Location: San Diego Convention Center, Hall GH

### About AUTO3

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently being tested in two clinical studies, AMELIA and ALEXANDER.

AMELIA is a single-arm, open label, multi-center Phase 1/2 clinical trial of AUTO3 in patients up to 24 years of age with high-risk relapsed or refractory B-lineage. The trial is also enrolling patients who previously received CD19 or CD22 targeting therapies including other CAR T cell therapy. The purpose of this study is to test the safety and efficacy, including the complete remission rate or minimal residual disease (MRD) negative response, of AUTO3. Autolus expects to enroll up to 54 patients in this trial.

ALEXANDER is a single-arm, open label, multi-center Phase 1/2 clinical trial of AUTO3 in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). The purpose of this study is to test the safety and efficacy, including the overall response rate as per Lugano criteria, of AUTO3 followed by limited duration of consolidation with anti-PD1 antibody. Autolus expects to enroll up to 120 patients in this trial.

For more information about these trials and the inclusion criteria, visit www.ClinicalTrials.gov.

### About AUTO5

AUTO5 is a programmed T cell therapy that leverages a new targeting approach based on the mutually exclusive expression of two subtypes of the T-cell receptor beta chain. Normal T-cells contain either TRBC1 or TRBC2 and each human has normal T cells of either type. In contrast, T cell

lymphoma cells are clonal and derived from a single mature T cell and so express either TRBC1 or TRBC2, but not both. AUTO5 targets TRBC2, and a separate product candidate known as AUTO4 targets TRBC1. This therapeutic approach uses a companion diagnostic to identify if the T cell lymphoma is TRBC1 or TRBC2 positive, and by using either AUTO4, or AUTO5 is designed to eliminate the portion of T cells containing the lymphoma, while preserving a healthy T cell sub-population to maintain cellular immunity. AUTO5 is in preclinical development.

For more information about this trial and the inclusion criteria, visit <u>www.ClinicalTrials.gov</u>.

#### **About Autolus Therapeutics plc**

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: <a href="https://www.autolus.com">https://www.autolus.com</a>

#### **Forward-Looking Statements**

This press release contains certain forward-looking statements regarding Autolus Therapeutics' research and development programs, including expectations regarding the enrollment of patients in our clinical trials. These statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Autolus Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in the Company's registration statement on Form F-1 and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements. Autolus Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investor contact:	International Media Contact:	U.S. Media Contact:
S.A. Noonan Communications	JW Communications	Rx Communications Group, LLC
Susan A. Noonan	Julia Wilson	Paula Schwartz
+1-212-966-3650	+44 (0)7818 430877	+ 1-917-322-2216
<u>susan@sanoonan.com</u>	juliawilsonuk@gmail.com	pschwartz@rxir.com

C View original content:http://www.prnewswire.com/news-releases/autolus-therapeutics-to-present-new-data-on-its-advanced-programmed-t-celltherapies-at-the-60th-ash-annual-meeting-300742217.html

SOURCE Autolus Therapeutics plc